- QCOR shares were off approximately 29% yesterday on a negative report from Citron Research. Analysts including Oppenheimer and Jefferies are out defending the stock this … Continue Reading
Read nowInsights - Shire Plc (SHPG) confirmed before the open on Friday said that it has rejected a $46 billion bid from AbbVie (ABBV), which represented a 25% premium … Continue Reading
Read nowRecap - These trades aren’t over yet, and you can catch up on the fundamental theses at PropThink.com. Below, our weekly recap. Shares of Biodelivery Sciences (BDSI) came close to … Continue Reading
Read nowResearch - Retrophin management has pinned shareholders and potential investors between a rock and a hard spot, but there's reason to be optimistic.
PremiumInsights - With the release of its full-year ’13 and Q4 financials on Thursday, Alexion Pharmaceuticals (ALXN) beat on both earnings and revenue, now guiding for 2014 … Continue Reading
Read nowInsights - It’s New Year’s Eve. This year flew past – and so did biotech. The NASDAQ Biotechnology Index (NBI) will end the year up 60%, while … Continue Reading
Read nowInsights - On the heels of dropping its bid to acquire troubled Transcept Pharmaceuticals (TSPT), Retrophin, Inc. (RTRX) announced its newest clinical development candidate on Wednesday: RE-034 … Continue Reading
Read now
